BEAM - Beam Therapeutics GAAP EPS of -$1.08 beats by $0.31 revenue of $20.12M beats by $3.27M
2023-08-08 07:51:36 ET
- Beam Therapeutics press release ( NASDAQ: BEAM ): Q2 GAAP EPS of -$1.08 beats by $0.31 .
- Revenue of $20.12M (+20.8% Y/Y) beats by $3.27M .
- Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2023, will enable the company to fund its anticipated operating expenses and capital expenditure requirements at least into 2025.
For further details see:
Beam Therapeutics GAAP EPS of -$1.08 beats by $0.31, revenue of $20.12M beats by $3.27M